Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.

Johnson RF, Kurup D, Hagen KR, Fisher C, Keshwara R, Papaneri A, Perry DL, Cooper K, Jahrling PB, Wang JT, Ter Meulen J, Wirblich C, Schnell MJ.

J Infect Dis. 2016 Oct 15;214(suppl 3):S342-S354.

PMID:
27456709
2.

Inactivation of RNA Viruses by Gamma Irradiation: A Study on Mitigating Factors.

Hume AJ, Ames J, Rennick LJ, Duprex WP, Marzi A, Tonkiss J, Mühlberger E.

Viruses. 2016 Jul 22;8(7). pii: E204. doi: 10.3390/v8070204.

3.

Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Clarke DK, Hendry RM, Singh V, Rose JK, Seligman SJ, Klug B, Kochhar S, Mac LM, Carbery B, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group..

Vaccine. 2016 Dec 12;34(51):6597-6609. doi: 10.1016/j.vaccine.2016.06.071.

PMID:
27395563
4.

Neglected filoviruses.

Burk R, Bollinger L, Johnson JC, Wada J, Radoshitzky SR, Palacios G, Bavari S, Jahrling PB, Kuhn JH.

FEMS Microbiol Rev. 2016 Jul;40(4):494-519. doi: 10.1093/femsre/fuw010. Review.

PMID:
27268907
5.

A web-based resource for designing therapeutics against Ebola Virus.

Dhanda SK, Chaudhary K, Gupta S, Brahmachari SK, Raghava GP.

Sci Rep. 2016 Apr 26;6:24782. doi: 10.1038/srep24782.

6.

Ebola virus vaccines - reality or fiction?

Mire CE, Geisbert TW, Feldmann H, Marzi A.

Expert Rev Vaccines. 2016 Nov;15(11):1421-1430.

PMID:
27078187
7.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316.

8.

Stat1-Deficient Mice Are Not an Appropriate Model for Efficacy Testing of Recombinant Vesicular Stomatitis Virus-Based Filovirus Vaccines.

Marzi A, Kercher L, Marceau J, York A, Callsion J, Gardner DJ, Geisbert TW, Feldmann H.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S404-9. doi: 10.1093/infdis/jiv188.

9.

Lack of protection against ebola virus from chloroquine in mice and hamsters.

Falzarano D, Safronetz D, Prescott J, Marzi A, Feldmann F, Feldmann H.

Emerg Infect Dis. 2015 Jun;21(6):1065-7. doi: 10.3201/eid2106.150176.

10.

A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.

Mire CE, Geisbert JB, Versteeg KM, Mamaeva N, Agans KN, Geisbert TW, Connor JH.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S384-8. doi: 10.1093/infdis/jiv126.

11.

Postmortem stability of Ebola virus.

Prescott J, Bushmaker T, Fischer R, Miazgowicz K, Judson S, Munster VJ.

Emerg Infect Dis. 2015 May;21(5):856-9. doi: 10.3201/eid2105.150041.

12.

Ebola, the killer virus.

Ghazanfar H, Orooj F, Abdullah MA, Ghazanfar A.

Infect Dis Poverty. 2015 Apr 8;4:15. doi: 10.1186/s40249-015-0048-y.

13.

Safety of recombinant VSV-Ebola virus vaccine vector in pigs.

de Wit E, Marzi A, Bushmaker T, Brining D, Scott D, Richt JA, Geisbert TW, Feldmann H.

Emerg Infect Dis. 2015 Apr;21(4):702-4. doi: 10.3201/eid2104.142012.

14.

Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy.

Chippaux JP, Boyer LV, Alagón A.

J Venom Anim Toxins Incl Trop Dis. 2015 Feb 15;21:3. doi: 10.1186/s40409-015-0003-1.

15.

The UCSC Ebola Genome Portal.

Haeussler M, Karolchik D, Clawson H, Raney BJ, Rosenbloom KR, Fujita PA, Hinrichs AS, Speir ML, Eisenhart C, Zweig AS, Haussler D, Kent WJ.

PLoS Curr. 2014 Nov 7;6. pii: ecurrents.outbreaks.386ab0964ab4d6c8cb550bfb6071d822. doi: 10.1371/currents.outbreaks.386ab0964ab4d6c8cb550bfb6071d822.

16.

Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection.

Daaboul GG, Lopez CA, Chinnala J, Goldberg BB, Connor JH, Unlü MS.

ACS Nano. 2014 Jun 24;8(6):6047-55. doi: 10.1021/nn501312q.

17.

Ebola virus vaccines: an overview of current approaches.

Marzi A, Feldmann H.

Expert Rev Vaccines. 2014 Apr;13(4):521-31. doi: 10.1586/14760584.2014.885841. Review.

18.

Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.

Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW.

PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600.

19.

Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Choi JH, Croyle MA.

BioDrugs. 2013 Dec;27(6):565-83. doi: 10.1007/s40259-013-0046-1. Review.

20.

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110.

Supplemental Content

Support Center